For more than two decades, since it was approved by the U.S. Food and Drug Administration (FDA), medication abortion has been a safe, timely, and evidence-based treatment for patients across the globe. Telemedicine abortion offers greater freedom for everyone to make their own reproductive health decisions and is now the most common form of abortion in the U.S. The two-step process of mifepristone and misoprostol is an FDA-approved method for terminating early pregnancies up to 12 weeks and can be done in the comfort of a patient’s home with the support of a telemedicine provider. Access to medication abortion via telehealth is also critical for treating the communities most impacted by the overturning of Roe v Wade, particularly BIPOC, LGBTQ+, low-income, disabled, and rural patients – many of whom experience higher maternal mortality rates and significant barriers to care.